Skip to content

Study · Animal study (in vivo) · rat · 2009

8 results

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.

Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Benedetti A

Gut1 Oct 2008Cited by 59 (Europe PMC)

PMID18829977 (opens in a new tab)PMCIDPMC2695839 (opens in a new tab)DOI10.1136/gut.2008.150870 (opens in a new tab)PepBankPUB-18829977
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In bile duct-ligated rats given CCl(4), exendin‑4 prevented the increase in TUNEL-positive cholangiocytes.

    In plain wordsIn rats with bile duct ligation given CCl(4), exendin‑4 prevented an increase in bile duct cells with DNA damage.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTUNEL-positive cholangiocytes
    Study

    ratn: not reported in source

    Bile duct-ligated rats treated with CCl(4)
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    In vivo, exendin-4 administration prevented the increase in TUNEL (terminal deoxynucleotidyl transferase-mediated triphosphate end-labelling)-positive cholangiocytes and the loss of bile ducts observed in bile duct-ligated rats treated with CCl(4).
    1 context sentence
    Summary · context
    in vivo, animals subjected to 1 week of bile duct ligation and to a single intraperitoneal injection of CCl(4) were treated with exendin-4 for 3 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In bile duct-ligated rats given CCl(4), exendin‑4 prevented bile duct loss.

    In plain wordsIn rats with bile duct ligation given CCl(4), exendin‑4 prevented bile duct loss.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBile duct loss
    Study

    ratn: not reported in source

    Bile duct-ligated rats treated with CCl(4)
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 3 daysAs given in this study (rat).

    Source sentences

    Summary
    In vivo, exendin-4 administration prevented the increase in TUNEL (terminal deoxynucleotidyl transferase-mediated triphosphate end-labelling)-positive cholangiocytes and the loss of bile ducts observed in bile duct-ligated rats treated with CCl(4).
    1 context sentence
    Summary · context
    in vivo, animals subjected to 1 week of bile duct ligation and to a single intraperitoneal injection of CCl(4) were treated with exendin-4 for 3 days.
  3. 03LabIn vitro (cells)Mechanism

    In isolated rat cholangiocytes, exendin‑4 prevented GCDCA-induced Bax mitochondrial translocation.

    In plain wordsIn cells from rats, exendin‑4 prevented GCDCA-induced movement of Bax into mitochondria.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBax mitochondrial translocation
    Study

    ratn: not reported in source

    Isolated normal rat cholangiocytes exposed to GCDCA
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 prevented GCDCA-induced Bax mitochondrial translocation, cytochrome c release and an increase in caspase 3 activity.
    1 context sentence
    Summary · context
    In vitro, tests were carried out to determine if exendin-4 is able to prevent apoptosis of cholangiocytes isolated from normal rats induced by glycochenodeoxycholic acid (GCDCA);
  4. 04LabIn vitro (cells)Mechanism

    In isolated rat cholangiocytes, exendin‑4 prevented GCDCA-induced cytochrome c release.

    In plain wordsIn cells from rats, exendin‑4 prevented GCDCA-induced cytochrome c release.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCytochrome c release
    Study

    ratn: not reported in source

    Isolated normal rat cholangiocytes exposed to GCDCA
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 prevented GCDCA-induced Bax mitochondrial translocation, cytochrome c release and an increase in caspase 3 activity.
    1 context sentence
    Summary · context
    In vitro, tests were carried out to determine if exendin-4 is able to prevent apoptosis of cholangiocytes isolated from normal rats induced by glycochenodeoxycholic acid (GCDCA);
  5. 05LabIn vitro (cells)Mechanism

    In isolated rat cholangiocytes, exendin‑4 prevented the GCDCA-induced increase in caspase 3 activity.

    In plain wordsIn cells from rats, exendin‑4 prevented the GCDCA-induced rise in caspase 3 activity.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCaspase 3 activity
    Study

    ratn: not reported in source

    Isolated normal rat cholangiocytes exposed to GCDCA
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 prevented GCDCA-induced Bax mitochondrial translocation, cytochrome c release and an increase in caspase 3 activity.
    1 context sentence
    Summary · context
    In vitro, tests were carried out to determine if exendin-4 is able to prevent apoptosis of cholangiocytes isolated from normal rats induced by glycochenodeoxycholic acid (GCDCA);

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 06LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In rat cholangiocytes, phosphatidylinositol 3-kinase inhibition neutralised the effects of exendin‑4.

    In plain wordsIn cells from rats, a PI3K inhibitor blocked exendin‑4 effects compared with exendin‑4 without inhibitor.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePI3K inhibitor blockade of exendin-4 effects
    Study

    ratn: not reported in source

    Isolated rat cholangiocytes
    Comparator
    Exendin-4 without inhibitor
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    Phosphatidylinositol 3-kinase, but not cAMP/protein kinase A or Ca(2+)/calmodulin-dependent protein kinase inhibitors, neutralised the effects of exendin-4.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 07LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In rat cholangiocytes, cAMP/protein kinase A inhibitors did not neutralise the effects of exendin‑4.

    In plain wordsIn cells from rats, cAMP/protein kinase A inhibitors did not block exendin‑4 effects compared with exendin‑4 without inhibitor.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changecAMP/protein kinase A inhibitor interaction
    Study

    ratn: not reported in source

    Isolated rat cholangiocytes
    Comparator
    Exendin-4 without inhibitor
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    Phosphatidylinositol 3-kinase, but not cAMP/protein kinase A or Ca(2+)/calmodulin-dependent protein kinase inhibitors, neutralised the effects of exendin-4.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 08LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In rat cholangiocytes, Ca(2+)/calmodulin-dependent protein kinase inhibitors did not neutralise the effects of exendin‑4.

    In plain wordsIn cells from rats, calcium/calmodulin-dependent protein kinase inhibitors did not block exendin‑4 effects compared with exendin‑4 without inhibitor.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCalmodulin-dependent protein kinase inhibitor interaction
    Study

    ratn: not reported in source

    Isolated rat cholangiocytes
    Comparator
    Exendin-4 without inhibitor
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    Phosphatidylinositol 3-kinase, but not cAMP/protein kinase A or Ca(2+)/calmodulin-dependent protein kinase inhibitors, neutralised the effects of exendin-4.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.